secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001193125-23-053829
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q4 net sales $74.4M, up 10.3% YoY; adjusted EBITDA $7.3M; new CEO Capper appointed
--------------------------------------------------------------------------------

- Q4 net sales $74.4M (+10.3% YoY); full year $267.8M (+3.6%). Highest quarterly since Q4 2019.
- Q4 net loss $0.4M vs net income $2.2M in prior year; FY net loss $30.2M vs $10.3M.
- Adjusted EBITDA Q4 $7.3M (improved from $3.6M); FY adjusted EBITDA $3.9M (from $18.7M).
- Appointed Joseph H. Capper as CEO and Director; Ricci S. Whitlow as COO.
- Commenced first registrational trial of mDHACM for knee osteoarthritis; launched EPIFIX in Japan via GUNZE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/0001193125-23-053829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312523053829/d439845d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-053829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer